AstraZeneca PLC (AZN)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about AstraZeneca PLC (AZN)
Company Performance

Current Price

as of Oct 11, 2024

$153.78

P/E Ratio

35.72

Market Cap

$238.53B

Description

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Metrics

Overview

  • HQCambridge, CA
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerAZN
  • Price$153.782803-0.05%

Trading Information

  • Market Cap$238.53B
  • Float94.26%
  • Average Daily Volume (1m)1,532,627
  • Average Daily Volume (3m)1,272,443
  • EPS$3.30

Company

  • Revenue$39.03B
  • Rev Growth (1yr)12.44%
  • Net Income$1.53B
  • Gross Margin75.69%
  • EBITDA Margin31.84%
  • EBITDA$3.26B
  • EV$213.75B
  • EV/Revenue5.48
  • P/E35.72
  • P/S4.70
  • P/B5.84
Documents
Factset Street Account
StreetAccount Metrics Recap - AstraZeneca Q3 Earnings (10170.0000p, 0) (2023-11-10T17:53:03Z)
StreetAccount Earnings Call Q&A Summary: AstraZeneca Q3 (10436.0000p, 0) (2023-11-09T18:25:22Z)
StreetAccount Consensus Metrics Preview - AstraZeneca Q3 Earnings (10270.0000p, +40) (2023-11-08T10:29:58Z)
Street Takeaways - AstraZeneca Q3 Earnings (10464.0000p, +294) (2023-11-09T10:37:08Z)
FDA grants orphan drug designation to selumetinib for malignant glioma ($64.15, +0.36) (2023-11-21T14:53:27Z)
FDA grants orphan drug designation to Imfinzi for gastric cancer including GEJC ($68.14, +0.13) (2023-10-12T18:52:46Z)
FDA grants orphan drug designation to Alexion (AZN.LN) drug for the treatment of transthyretin amyloidosis (10950.0000p, 0) (2023-10-02T16:15:50Z)
FDA approves efficacy supplement (sNDA) for Lynparza ($64.05, 0.00) (2023-11-07T14:09:49Z)
EU's CHMP adopted a positive opinion recommending a change to the terms of the marketing authorisation for AstraZeneca's Imfinzi (11010.0000p, -110) (2023-10-13T12:04:06Z)
AstraZeneca's Soliris approved in China for the treatment of adults with neuromyelitis optica spectrum disorder (11270.0000p, 0) (2023-10-18T06:07:28Z)
AstraZeneca's PACIFIC-2 Phase III trial for Imfinzi concurrently administered with CRT did not achieve statistical significance for the primary endpoint (10248.0000p, 0) (2023-11-14T07:10:59Z)
AstraZeneca's FluMist Quadrivalent accepted for FDA sBLA review (10100.0000p, 0) (2023-10-24T06:08:16Z)
AstraZeneca's EMERALD Phase III trial for Imfinzi plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolisation (10170.0000p, 0) (2023-11-09T07:19:10Z)
AstraZeneca's Alexion Pharma Canada Corp enters into LoI with the pan-Canadian Pharmaceutical Alliance for Ultomiris (10232.0000p, +132) (2023-10-24T11:04:52Z)
AstraZeneca will present new clinical and real-world data in multiple haematological conditions at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA, 9 to 12 December 2023. (9900.0000p, 0) (2023-11-29T07:05:31Z)
AstraZeneca settles Nexium and Prilosec product liability litigations (10950.0000p, 0) (2023-10-03T06:03:35Z)
AstraZeneca says China has clarified its anti-corruption focus is on hospital management and not drug companies - London Times (10270.0000p, 0) (2023-11-06T00:22:47Z)
AstraZeneca reports Q3 Core EPS $1.73 vs consensus $1.69. Updates FY 2023 outlook based on the average foreign exchange rates (10170.0000p, 0) (2023-11-09T07:11:40Z)
AstraZeneca licenses novel agent for the treatment of cardiometabolic conditions and obesity (10170.0000p, 0) (2023-11-09T14:40:07Z)
AstraZeneca has decided to discontinue STABILIZE-CKD and DIALIZE-Outcomes Phase III evidence trials for Lokelma (10126.0000p, 0) (2023-12-01T07:04:52Z)
AstraZeneca expanding collaboration with Vanguard Renewables to boost US RNG productivity (10280.0000p, +50) (2023-11-08T12:10:53Z)
AstraZeneca CEO Pascal Soriot moves to Australia - Mail on Sunday (10974.0000p, 0) (2023-10-14T22:52:43Z)
AstraZeneca CEO Pascal Soriot commits to leading the company for another five years - London Times (10438.0000p, 0) (2023-10-24T23:33:01Z)
AstraZeneca announces Zibotentan/dapagliflozin combination demonstrated significant albuminuria reduction in patients with chronic kidney disease and proteinuria in ZENITH-CKD Phase IIb trial (10244.0000p, -118) (2023-11-03T15:32:32Z)
AstraZeneca announces Imfinzi plus chemotherapy approved in China for patients with locally advanced or metastatic biliary tract cancer (10248.0000p, 0) (2023-11-14T07:07:41Z)
Wikipedia
AstraZeneca_PLC
Factset
Factset Business Description